Forleo Giovanni B, Santini Luca, Romeo Francesco
Giovanni B Forleo, Luca Santini, Francesco Romeo, Division of Cardiology, Department of Internal Medicine, University of Rome "Tor Vergata", Viale Oxford, 81, 00133 Rome, Italy.
World J Cardiol. 2009 Dec 31;1(1):11-22. doi: 10.4330/wjc.v1.i1.11.
Atrial fibrillation (AF) management requires knowledge of its pattern of presentation, underlying conditions, and decisions about restoration and maintenance of sinus rhythm, control of the ventricular rate, and anti-thrombotic therapy. Maintenance of sinus rhythm is a desirable goal in AF patients because the prevention of recurrence may improve cardiac function, relieve symptoms and reduce the likelihood of adverse events. Anti-arrhythmic drug therapy is the first-line treatment for patients with paroxysmal and persistent AF based on current guidelines. However, currently used drugs have limited efficacy and cause cardiac and extracardiac toxicity. Thus, there is a continued need to develop new drugs, device and ablative approaches to rhythm management. Additionally, simpler and safer stroke prevention regimens are needed for AF patients on life-long anticoagulation, including occlusion of the left atrial appendage. The results of the Randomized Evaluation of Long-Term Anticoagulant Therapy study are encouraging in these settings. Knowledge on the pathophysiology of AF is rapidly expanding and identification of focally localized triggers has led to the development of new treatment options for this arrhythmia. Conversely, the clinical decision whether to restore and maintain sinus rhythm or simply control the ventricular rate has remained a matter of intense debate. In the minority of patients in whom AF cannot be adequately managed by pharmacological therapy, the most appropriate type of non-pharmacological therapy must be selected on an individualized basis. Curative treatment of AF with catheter ablation is now a legitimate option for a large number of patients. The evolution of hybrid therapy, in which two or more different strategies are employed in the same patient, may be an effective approach to management of AF. In any case, planning a treatment regimen for AF should include evaluation of the risks inherent in the use of various drugs as well as more invasive strategies.
心房颤动(AF)的管理需要了解其临床表现模式、潜在病因,以及关于恢复和维持窦性心律、控制心室率和抗血栓治疗的决策。维持窦性心律是房颤患者的一个理想目标,因为预防复发可能改善心脏功能、缓解症状并降低不良事件的发生可能性。根据当前指南,抗心律失常药物治疗是阵发性和持续性房颤患者的一线治疗方法。然而,目前使用的药物疗效有限,并会导致心脏和心脏外毒性。因此,持续需要开发新的药物、装置和消融方法来进行节律管理。此外,对于需要终身抗凝的房颤患者,需要更简单、更安全的中风预防方案,包括封堵左心耳。长期抗凝治疗随机评估研究的结果在这些情况下令人鼓舞。关于房颤病理生理学的知识正在迅速扩展,局灶性触发因素的识别已导致针对这种心律失常开发新的治疗选择。相反,关于是恢复并维持窦性心律还是仅控制心室率的临床决策仍然是一个激烈争论的问题。在少数药物治疗无法充分管理房颤的患者中,必须根据个体情况选择最合适的非药物治疗类型。导管消融根治房颤现在是大量患者的合理选择。在同一患者中采用两种或更多不同策略的混合治疗的发展,可能是管理房颤的有效方法。无论如何,制定房颤治疗方案应包括评估使用各种药物以及更具侵入性策略所固有的风险。